WHO WE ARE

Edge is a private, hospital-focused specialty pharmaceutical company that transforms proven, FDA-approved drugs into targeted, locally delivered...

WHAT WE DO

Edge is developing novel and proprietary microparticle formulations of known active drugs that deliver optimal concentrations, sustained for the...

WHAT’S NEW

MPI Research and Edge Therapeutics Partner to Advance Development of Life-Saving Therapies After Brain Hemorrhage.  Drugs Utilize Novel...

WHAT IS SUBARACHNOID HEMORRHAGE

Subarachnoid hemorrhage (SAH) is bleeding into the space around the brain that is filled with cerebrospinal fluid (the subarachnoid space). A...

• 
• 

Welcome to Edge Therapeutics, Inc.

Edge Therapeutics is a hospital-focused biopharmaceutical company started in 2009. Edge transforms proven, known active agents into targeted, locally delivered therapies that address acute, fatal and debilitating neurological conditions. Edge's lead products are in front of two trends simultaneously occurring in the neurosurgical marketplace; the transition of microsurgical clipping to endovascular coiling in the aneurysmal subarachnoid hemorrhage (aSAH) treatment marketplace, more commonly known as ruptured brain aneurysms, and the aging population or graying of the world causing an increase in chronic subdural hematomas. Overall, the Company's robust portfolio of three novel products addressing six unique indications is designed to fundamentally change how brain injuries associated with bleeding are treated.

Click to view recent feature articles on Edge: